Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:07 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2
NCT06006143 · Yale University · PHASE2 · terminated · last registry update 2026-11-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “recruitment challenges” | – | Registry record, Yale University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CHRNB2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-05Results posted on the registry: Albert Einstein College of Medicine, a drug against CHRNB2 (NCT05997225)
- 2026-11-05Results posted on the registry: Washington State University, Nicotine gum (2.5 mg) + Letrozole (2.5 mg) (NCT05157672)
- 2026-10-27Results posted on the registry: Real Prevention, LLC, a drug against CHRNB2 (NCT03932097)
- 2026-10-26Also stopped (terminated): Washington University School of Medicine, a drug against CHRNB2 (NCT05994209)
- 2026-10-23Results posted on the registry: The University of Hong Kong, a drug against CHRNB2 (NCT05393349)
- 2026-10-16Also stopped (terminated): Fred Hutchinson Cancer Center, a drug against CHRNB2 (NCT07571018)
- 2026-10-15Results posted on the registry: Mark J Rzeszutek, PhD, a drug against CHRNB2 (NCT07010601)
- 2026-10-09Also stopped (withdrawn): University of Missouri-Columbia, a drug against CHRNB2 (NCT06347055)
- 2026-10-09Also stopped (withdrawn): University of Missouri-Columbia, a drug against CHRNB2 (NCT05389670)
- 2026-10-02Results posted on the registry: Yale University, a drug against CHRNB2 (NCT05432830)
- 2026-09-25Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, Nicotine patch + Nicotine lozenge (NCT05014282)
- 2026-09-18Results posted on the registry: American University of Beirut Medical Center, e-liquid 1 + e-liquid 2 (NCT05430334)
- 2026-09-17Results posted on the registry: University of Southern California, Nicotine Transdermal Patch + Placebo Patch (NCT02720445)
- 2026-09-17Also stopped (withdrawn): ProofPilot, a drug against CHRNB2 (NCT03266666)
- 2026-09-15Also stopped (withdrawn): Virginia Polytechnic Institute and State University, a drug against CHRNB2 (NCT07042373)
- 2026-09-08Results posted on the registry: University of Utah, a drug against CHRNB2 (NCT03900767)
- 2026-08-31Results posted on the registry: Seattle Institute for Biomedical and Clinical Research, a drug against CHRNB2 (NCT04505371)
- 2026-08-31Results posted on the registry: University of Iowa, a drug against CHRNB2 (NCT06943287)
- 2026-08-25Results posted on the registry: Duke University, Varenicline (NCT06029907)
- 2026-08-20Results posted on the registry: Butler Hospital, Electronic Cigarette + Nicotine Lozenge (NCT05206435)
- 2026-08-18Results posted on the registry: Medical University of South Carolina, Contingency Management + Standard Care (NCT04605458)
- 2026-08-14Results posted on the registry: Ottawa Heart Institute Research Corporation, NicoDerm Patch + Nicorette Inhaler (NCT01622998)
- 2026-08-13Results posted on the registry: Florida International University, a drug against CHRNB2 (NCT05205382)
- 2026-08-10Results posted on the registry: Ottawa Heart Institute Research Corporation, Cost-Free Pharmacotherapy Group (NCT00962988)
- 2026-08-07Results posted on the registry: Institut Cancerologie de l'Ouest, Nicotine Replacement Therapy (NRT) (NCT04899492)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision